CDKN2A and glioblastoma: Reduces oncogene (ADAM19, EPHA3, KLF4) and upregulates tumor suppressor (CDKN2A, BRCA2, TP53I11) expression, inhibits GSC growth, self-renewal in vitro, and glioblastoma progression in vivo